These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Defucosylated Mouse-Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors. Li G; Ohishi T; Kaneko MK; Takei J; Mizuno T; Kawada M; Saito M; Suzuki H; Kato Y Cells; 2021 Dec; 10(12):. PubMed ID: 34944112 [TBL] [Abstract][Full Text] [Related]
24. Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody. Huang S; Li F; Liu H; Ye P; Fan X; Yuan X; Wu Z; Chen J; Jin C; Shen B; Feng J; Zhang B MAbs; 2018; 10(6):864-875. PubMed ID: 30081724 [TBL] [Abstract][Full Text] [Related]
25. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity. Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556 [TBL] [Abstract][Full Text] [Related]
26. Antitumor Activities in Mouse Xenograft Models of Canine Fibroblastic Tumor by Defucosylated Anti-Epidermal Growth Factor Receptor Monoclonal Antibody. Goto N; Suzuki H; Ohishi T; Harakawa A; Li G; Saito M; Takei J; Tanaka T; Asano T; Sano M; Kawada M; Kaneko MK; Kato Y Monoclon Antib Immunodiagn Immunother; 2022 Apr; 41(2):67-73. PubMed ID: 35377239 [TBL] [Abstract][Full Text] [Related]
27. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers. Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946 [TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes. Jain R; Rawat A; Verma B; Markiewski MM; Weidanz JA J Natl Cancer Inst; 2013 Feb; 105(3):202-18. PubMed ID: 23300219 [TBL] [Abstract][Full Text] [Related]
29. TrMab-6 Exerts Antitumor Activity in Mouse Xenograft Models of Breast Cancers. Tanaka T; Ohishi T; Saito M; Kawada M; Kaneko MK; Kato Y Monoclon Antib Immunodiagn Immunother; 2022 Feb; 41(1):32-38. PubMed ID: 35225665 [TBL] [Abstract][Full Text] [Related]
31. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2. Maadi H; Nami B; Tong J; Li G; Wang Z BMC Cancer; 2018 Mar; 18(1):238. PubMed ID: 29490608 [TBL] [Abstract][Full Text] [Related]
32. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834 [TBL] [Abstract][Full Text] [Related]
33. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333 [TBL] [Abstract][Full Text] [Related]
35. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208 [TBL] [Abstract][Full Text] [Related]
36. Proteolytic single hinge cleavage of pertuzumab impairs its Fc effector function and antitumor activity in vitro and in vivo. Hsiao HC; Fan X; Jordan RE; Zhang N; An Z Breast Cancer Res; 2018 Jun; 20(1):43. PubMed ID: 29859099 [TBL] [Abstract][Full Text] [Related]